# Semaglutide for Smoking Cessation in Patients With Diabetes

Study · id `cardio:ct-nct07059377` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07059377](<https://clinicaltrials.gov/study/NCT07059377>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07059377

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT07059377. Randomized; no masking; primary purpose treatment. Start 2026-02-13 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT07059377, source copy `cardio:ctgov-nct07059377-2026-09-08`, retrieved 2026-10-26)
- Started: 2026-02-13 (actual) (ClinicalTrials.gov record NCT07059377, source copy `cardio:ctgov-nct07059377-2026-09-08`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07059377, source copy `cardio:ctgov-nct07059377-2026-09-08`, retrieved 2026-10-26)
- Completion: 2027-07 (anticipated) (ClinicalTrials.gov record NCT07059377, source copy `cardio:ctgov-nct07059377-2026-09-08`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT07059377, source copy `cardio:ctgov-nct07059377-2026-09-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07059377-2026-09-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Semaglutide for Smoking Cessation in Patients With Diabetes
- Acronym: GLP1-SC
- Condition: Diabetes Mellitus, Type 2
- Condition: Nicotine Addiction
- Condition: Tobacco Dependence
- Intervention (Drug): Semaglutide
- Intervention (Drug): Nicotine replacement
- Lead sponsor: Ottawa Heart Institute Research Corporation
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Ottawa Heart Institute Research Corporation (`cardio:org-ottawa-heart-institute-research-corporation`)

## Provenance

Content hash: 6f6f76064bd2125adeec410cf26d1aa305224f4c174d934ebe948f3d66e82ebf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
